Curasight’s CEO Ulrich Krasilnikoff comments:

"In the second quarter of 2025, we were pleased to complete a capital injection of around DKK 65 million from a mix of fresh capital and new and renegotiated loans. This funding allows us to build on our theranostic approach of using radiopharmacueticals to develop more gentle and targeted diagnosis and treatment of certain types of cancer. With this new financial foundation we can advance both our phase II trial with the uTRACE® diagnostic platform in prostate cancer and the phase I trial for uTREAT® in glioblastoma - where we recently received the regulatory green light from the European Medicines Agency to initiate the study and start enrolling patients".

Q2 (2025-04-01 – 2025-06-30)

• Gross loss amounted to kDKK -17,700 (kDKK -9,001)
• Operating loss amounted to kDKK -19,011 (kDKK -10,969)
• Loss before tax amounted to kDKK -20,579 (kDKK -12,112)
• Loss for the period amounted to kDKK -19,204 (kDKK -10,737)
• Total assets amounted to kDKK 44,783 (kDKK 28,847)
• Equity ratio amounted to 67.6% (43.9%)
• Earnings per share amounted to DKK -0.43 (DKK -0.54)

H1 (2025-01-01 – 2025-06-30)

• Gross loss amounted to kDKK -22,399 (kDKK -16,386)
• Operating loss amounted to kDKK -25,220 (kDKK -20,345)
• Loss before tax amounted to kDKK -27,158 (kDKK -21,479)
• Loss for the period amounted to kDKK -24,408 (kDKK -18,729)
• Total assets amounted to kDKK 44,783 (kDKK 28,847)
• Equity ratio amounted to 67.6% (43.9%)
• Earnings per share amounted to DKK -0.54 (DKK -0.94)

Numbers in parenthesis are the numbers from the same period in 2024.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com